7 results about "Serum transaminase" patented technology

This invention discloses a novel use of carvedilol or its salts and compositions, as well as the composition and its preparation method. The β-blocker or pharmaceutical composition provided by this invention has good efficacy in preventing, treating, and / or alleviating drug-induced liver injury, effectively reducing mortality caused by this disease; simultaneously, it can significantly reduce serum transaminase levels, alleviate symptoms such as liver and spleen edema, and has a good inhibitory effect on pro-inflammatory cytokines. Furthermore, experimental results further indicate that the combination of the β-blocker and pharmaceutically acceptable excipients (steviosides and / or glycyrrhizate) has good safety and is easily dissolved, released, and / or absorbed, improving the bioavailability of carvedilol and exhibiting a synergistic effect, showing promising application prospects.

This invention discloses a vitamin A-functionalized polyphenol-phospholipid complex, its preparation method, and its applications, belonging to the field of pharmaceutical formulation and nanodelivery technology. The phospholipid complex comprises a polyphenol drug, a phospholipid material, and a vitamin A phospholipid ligand. The vitamin A phospholipid ligand is formed by vitamin A or its derivatives and a phospholipid derivative containing amino or other reactive groups. The phospholipid complex forms a phospholipid composite structure through non-covalent interactions between the polyphenol drug and the phospholipid material, and the vitamin A phospholipid ligand is inserted into or assembled into the surface or interior of the phospholipid composite structure. Animal experiments show that this phospholipid complex can reduce serum transaminase levels and alleviate the degree of liver fibrosis, and has good blood compatibility and tissue safety. This invention provides an industrially achievable targeted nano-formulation solution for early intervention in liver fibrosis, with promising application prospects.

This invention relates to the application of PRMT4 inhibitors in the preparation of drugs for treating metabolic-associated steatohepatitis (MASH), belonging to the field of fatty liver disease treatment technology. This invention is the first to discover that PRMT4 inhibitors can serve as a novel drug target for treating MASH. Cellular experiments show that PRMT4 inhibitors inhibit palmitic acid-induced hepatocyte steatosis. Animal experiments confirm that PRMT4 inhibitors can improve hepatic fat deposition, inflammatory response, hepatocyte damage, fibrosis, and insulin resistance in high-fat fed mice, and reduce liver tissue and serum triglyceride and transaminase levels. This invention finds that PRMT4 inhibitors mainly inhibit the activation of YAP, a key transcriptional activator involved in lipid and inflammatory metabolism, and the expression of its downstream target genes. Therefore, PRMT4 inhibitors can be used to prepare drugs for treating MASH, with definite and significant efficacy, and have promising medical application prospects.

The application discloses application of an Ilicium fortunei extract in preparation of a product for preventing and treating non-alcoholic fatty liver disease. The Ilicium fortunei extract is prepared through a water extraction-alcohol precipitation-dialysis impurity removal and macroporous resin decolorization process, has a sugar content of 36.23+1.56%, a sugar acid content of 46.00+1.77%, a protein content of 1.03+0.02% and a polyphenol content of 0.07+0.001%. Experimental results show that the extract can significantly reduce the body weight, liver weight and serum transaminase level of a mouse with metabolic disorder induced by a high-fat diet, improve glucose tolerance and insulin resistance, reduce liver steatosis and inflammatory damage, and effectively regulate intestinal flora structure and restore microbial community balance, thereby playing an intervention role on metabolic related fatty liver disease. The application provides a scientific basis for a new use of the Ilicium fortunei extract in prevention and treatment of metabolic related fatty liver disease, and has a good application prospect.

The application discloses application of protosappanin A in preparation of a medicine for treating liver fibrosis, relates to the technical field of biological medicine, and is used for reducing liver fibrosis by targeting CHEK1-mediated proliferation of hepatic stellate cells; the protosappanin A is used for reducing inflammation infiltration, necrosis and collagen deposition of the liver in the liver fibrosis; the medicine comprises protosappanin A and pharmaceutically acceptable adjuvants; the medicine is used for inhibiting activation and / or proliferation of hepatic stellate cells; the medicine is used for reducing liver fibrosis by down-regulating expression levels of CHEK1; a medicine composition for treating liver fibrosis comprises an effective amount of protosappanin A and pharmaceutically acceptable adjuvants; the application discloses a new use of protosappanin A (PrA) in preparation of an anti-liver fibrosis medicine; in-vivo and in-vitro experiments prove that PrA can significantly reduce serum transaminase (ALT, AST) levels, and reduce inflammation infiltration, necrosis and collagen deposition of the liver.

The application discloses a kind of pharmaceutical compositions, it includes stilben compound and pharmaceutically acceptable adjuvant;Wherein, the stilben compound is Pterostilbene or its pharmaceutically acceptable salt, the pharmaceutically acceptable adjuvant includes glucosyl tangeritin and / or glycyrrhizic acid salt.The in vitro and / or in vivo test results show that the pharmaceutical composition provided by the application has good curative effect for preventing and / or treating drug-induced liver injury;Meanwhile, it can also significantly reduce serum transaminase level, alleviate the symptoms such as liver and spleen edema, and also has good inhibitory effect on proinflammatory cytokines.The test results further show that stilben compound and pharmaceutically acceptable adjuvant (including glucosyl tangeritin and / or glycyrrhizic acid salt) combination, good safety, and easy to dissolve, release and / or absorption etc., improve the bioavailability of Pterostilbene (PTE), have synergistic effect, and have good application prospect.

This invention discloses the application of ornithine aspartate in the preparation of drugs for treating systemic aging. By applying ornithine aspartate to regulate the systemic aging process, this invention can effectively improve hepatocyte dysfunction, restore cell proliferation activity, alleviate cell cycle arrest, and reduce the abnormal expression of aging-related genes and proteins in multiple tissues and organs such as the liver, kidneys, heart, muscles, and fat, thereby delaying the aging process. This technical solution can significantly improve the structural disorder and lipid deposition in aging liver tissue, reduce serum transaminase levels, improve liver function, reduce insulin resistance, inhibit the overexpression of SASP-related inflammatory factors, and maintain metabolic homeostasis. Furthermore, it effectively improves aging phenotypes in multiple tissues and organs. Therefore, this invention has significant technical effects and application potential in delaying systemic aging and improving motor function and metabolic abnormalities.